Evidence map›Paper›PMID 37753082›Full record

Observational studyFrontiers in immunology2023

Glucose-6-phosphate dehydrogenase deficiency and long-term risk of immune-related disorders.

Ariel Israel, Alejandro A Schäffer, Matitiahu Berkovitch, David J Ozeri, Eugene Merzon, Ilan Green, Avivit Golan-Cohen, Eytan Ruppin, Shlomo Vinker, Eli Magen

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
8.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Next-Generation Probiotics in Allergy Therapy: Scientific Evidence and Clinical Applications.Anti-inflammatory & anti-allergy agents in medicinal chemistry · 2026
    Review
  5. Article
  6. Review
  7. Oxidative pentose phosphate pathway is required for T cell activation and antitumor immunity.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 2 countries.

Ariel IsraelLeumit Research Institute, Leumit Health Services, Tel Aviv-Yafo, Israel.
Alejandro A SchäfferCancer Data Science Laboratory, National Cancer Institute, Bethesda, MD, United States.
Matitiahu BerkovitchSchool of Public Health and Family Medicine Department, Faculty of Medicine, Tel Aviv University, Tel Aviv-Yafo, Israel.
David J OzeriLeumit Research Institute, Leumit Health Services, Tel Aviv-Yafo, Israel.
Eugene MerzonLeumit Research Institute, Leumit Health Services, Tel Aviv-Yafo, Israel.
Ilan GreenLeumit Research Institute, Leumit Health Services, Tel Aviv-Yafo, Israel.
Avivit Golan-CohenLeumit Research Institute, Leumit Health Services, Tel Aviv-Yafo, Israel.
Eytan RuppinCancer Data Science Laboratory, National Cancer Institute, Bethesda, MD, United States.
Shlomo VinkerLeumit Research Institute, Leumit Health Services, Tel Aviv-Yafo, Israel.
Eli MagenLeumit Research Institute, Leumit Health Services, Tel Aviv-Yafo, Israel.
Clalit Health Services · ILNational Cancer Institute · USAriel University · ILAssaf Harofeh Medical Center · ILSheba Medical Center · ILTel Aviv University · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Glucose-6-phosphate dehydrogenase (G6PD) deficiency is an X-linked enzymatic disorder that is particularly prevalent in Africa, Asia, and the Middle East. This study aimed to assess the long-term health risks associated with G6PD deficiency. Methods: A retrospective cohort study was conducted using data from a national healthcare provider in Israel (Leumit Health Services). A total of 7,473 G6PD-deficient individuals were matched with 29,892 control subjects in a 1:4 ratio, based on age, gender, socioeconomic status, and ethnic groups. The exposure of interest was recorded G6PD diagnosis or positive G6PD diagnostic test. The main outcomes and measures included rates of infectious diseases, allergic conditions, and autoimmune disorders between 2002 and 2022. Results: Significantly increased rates were observed for autoimmune disorders, infectious diseases, and allergic conditions in G6PD-deficient individuals compared to the control group. Specifically, notable increases were observed for rheumatoid arthritis (odds ratio [OR] 2.41, p<0.001), systemic lupus erythematosus (OR 4.56, p<0.001), scleroderma (OR 6.87, p<0.001), pernicious anemia (OR 18.70, p<0.001), fibromyalgia (OR 1.98, p<0.001), Graves' disease (OR 1.46, p=0.001), and Hashimoto's thyroiditis (OR 1.26, p=0.001). These findings were supported by elevated rates of positive autoimmune serology and higher utilization of medications commonly used to treat autoimmune conditions in the G6PD-deficient group. Discussion: In conclusion, individuals with G6PD deficiency are at a higher risk of developing autoimmune disorders, infectious diseases, and allergic conditions. This large-scale observational study provides valuable insights into the comprehensive association between G6PD deficiency and infectious and immune-related diseases. The findings emphasize the importance of considering G6PD deficiency as a potential risk factor in clinical practice and further research is warranted to better understand the underlying mechanisms of these associations.

Indexed as

Arthritis, RheumatoidAutoimmune DiseasesGlucosephosphate Dehydrogenase DeficiencyGraves DiseaseHypersensitivityGlucosephosphate DehydrogenaseHumansRetrospective StudiesG6PD protein, humanGlucosephosphate DehydrogenaseallergyautoimmunityfibromyalgiaG6PD deficiencyhidradenitis suppurativainfectious diseaseslupus (SLE)rheumatoid arthritis

Identifiers

PMID37753082
PMCPMC10518697
OpenAlexW4386603404

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.